Keywords: Pharming, Merger, Sale, Options, Ruconest, Hereditary angioedema

Pharming considers options, including a sale of the company

Article | 13 June 2012

Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is reviewing its strategic options and has engaged ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pharming

Go to company listing

Related Drugs

Ruconest

Go to drug listing